2 mg tirzepatide Mounjaro (tirzepatide) for the Treatment of Type Diabetes, USA Mounjaro (Tirzepatide) Weight Loss Injections

Every case is unique

Seek urgent care for persistent severe abdominal pain, signs of severe hypoglycemia, or signs of dehydration and reduced urine output

Rondanelli M et al

To view or add a comment, sign in More Relevant Posts New publication "Even with Diet and Exercise, Ozempic Use Reduces Perceived Effort and Praiseworthiness of Resulting Weight Loss" - led by Maria Bachmakova and published in Social Science & Medicine

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are now considered the first choice of injectable therapy for many people with T2D, with several members of the class having proven cardiovascular efficacy 3

TRULICITY is not for use in people with type 1 diabetes and is not recommended for use in people with severe stomach or intestinal problems